口服避孕药与健康非绝经女性药物诱导QT间期延长的关联
本研究纳入498名健康非绝经女性,接受80 mg索他洛尔后3小时评估心电图变化。结果显示,服用具有抗雄激素活性的屈螺酮者QTc延长幅度大于未服药者或服用左炔诺孕酮者,且T波改变频率更高;欧洲药物警戒数据库分析也显示屈螺酮相关QT延长和室性心律失常报告率高于左炔诺孕酮。
要点
- 服用屈螺酮者索他洛尔诱导的QTc延长幅度大于未服药或服用左炔诺孕酮者。
- 屈螺酮组T波改变频率高于左炔诺孕酮组和未服药组。
- 欧洲药物警戒数据库显示屈螺酮相关QT延长和室性心律失常报告率高于左炔诺孕酮。
核心结论
- 口服避孕药对健康非绝经女性药物诱导的心室复极改变存在差异,屈螺酮与索他洛尔诱导的QTc延长增加相关,但绝对延长幅度不大。
研究设计与样本
- 研究为队列研究,纳入498名健康非绝经女性,在临床研究中心接受80 mg口服索他洛尔,根据口服避孕药类型分组, enrollment时间为2008年2月至2012年2月。
临床怎么用
- 对于服用QTc延长药物的女性,可考虑评估其口服避孕药类型,尤其是使用具有抗雄激素活性的屈螺酮者。
- 需更多数据明确抗雄激素口服避孕药是否在服用QTc延长药物患者中导致临床显著不良事件。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Women are at higher risk of drug-induced torsade de pointes (TdP) than men. Androgens are protective. Influence of oral contraception on drug-induced TdP and QT prolongation is controversial. OBJECTIVE: To determine if the extent of sotalol-induced corrected QT (QTc) prolongation and specific T-wave morphological changes, which are biomarkers for the risk of drug-induced TdP, differ in patients according to the androgenic activity of the type of oral contraceptive (OCs) they take compared with patients who took no pills. DESIGN, SETTING, AND PARTICIPANTS: A cohort of 498 healthy, nonmenopausal women received 80 mg of oral sotalol, a drug with known risk of drug-induced TdP, during this study in a clinical investigation center. The participants also took either no oral contraception or received OCs with different types of progestin: levonorgestrel (which has high androgenic potency), desogestrel or gestodene (which has intermediate androgenic potency), or drospirenone (which has antiandrogenic properties). Women were enrolled from February 2008 to February 2012, and data analysis took place from September 2014 to May 2018. MAIN OUTCOMES AND MEASURES: Electrocardiographic changes 3 hours after sotalol administration. RESULTS: A total of 137 women received levonorgestrel, 41 received desogestrel, 51 received gestodene, and 62 received drospirenone; another 207 received no OCs. Baseline QTc duration, plasma sotalol levels, and potassium levels did not significantly differ among groups. However, 3 hours after sotalol exposure, QTc prolongation was greater in women taking drospirenone (mean [SD] increase, 31.2 [12.6] milliseconds from baseline) than in women taking no OCs (mean [SD] increase, 24.6 [12.5] milliseconds; P = .005) or those taking levonorgestrel (mean [SD] increase, 24.2 [13.7] milliseconds; P = .005). The frequency of sotalol-induced T-wave alteration was higher in women taking drospirenone (n = 13 of 61 [21.0%]) than those taking levonorgestrel (n = 20 of 137 [14.6%]) or women taking no OCs (n = 24 of 207 [11.6%]; P = .01). Disproportionality analysis using the European pharmacovigilance database showed a higher reporting rate of OC-induced prolonged QT and ventricular arrhythmias in women taking drospirenone than levonorgestrel (drug-induced long QT syndrome: reporting odds ratio [ROR], 6.2 [95% CI, 1.3-30.8]; P = .01; ventricular arrhythmia: ROR, 3.3 [95% CI, 1.7-6.3]; P < .001). CONCLUSIONS AND RELEVANCE: Contraceptive pills are associated with variable drug-induced alterations of ventricular repolarization in healthy nonmenopausal women. Drospirenone, an antiandrogenic pill, was associated with increased sotalol-induced QTc prolongation, although absolute QTc prolongation was modest. This finding was supported by the European pharmacovigilance database, which showed a higher reporting rate of suspected OC-induced ventricular arrhythmias on drospirenone compared with levonorgestrel. More data are required on whether antiandrogenic OCs lead to clinically significant adverse events in patients taking QTc-prolonging drugs.
引用
- Salem JE, Dureau P, Bachelot A, et al. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. JAMA Cardiol. 2018. PMID: 30073300. doi:10.1001/jamacardio.2018.2251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。